Vidac Pharma Holdings Plc Initiates Phase 2B Trial for Targeted Treatment of Highly Proliferative Actinic Keratosis
Vidac Pharma advances a Phase 2B trial with a novel approach to treating highly proliferative Actinic Keratosis Vidac Pharma Holdings Plc. (XDUS:T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ) LONDON, UNITED KINGDOM, December 11, 2025 /EINPresswire.com/ …